IRIS
TENTORI, LUCIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 49.108
EU - Europa 4.730
AS - Asia 1.535
SA - Sud America 25
Continente sconosciuto - Info sul continente non disponibili 8
AF - Africa 7
OC - Oceania 2
Totale 55.415
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 49.062
IT - Italia 1.453
SG - Singapore 750
UA - Ucraina 730
DE - Germania 677
CN - Cina 530
IE - Irlanda 423
FR - Francia 417
SE - Svezia 255
PL - Polonia 223
GB - Regno Unito 173
FI - Finlandia 151
KR - Corea 140
RU - Federazione Russa 124
JP - Giappone 37
CA - Canada 34
CZ - Repubblica Ceca 29
IN - India 29
NL - Olanda 27
BE - Belgio 14
MX - Messico 11
BR - Brasile 9
CO - Colombia 9
IR - Iran 9
EU - Europa 8
IL - Israele 8
ES - Italia 7
BG - Bulgaria 6
CH - Svizzera 6
HK - Hong Kong 6
CL - Cile 5
VN - Vietnam 5
EG - Egitto 4
KG - Kirghizistan 4
MK - Macedonia 4
PH - Filippine 4
AT - Austria 3
ID - Indonesia 3
TW - Taiwan 3
DK - Danimarca 2
MW - Malawi 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AU - Australia 1
BD - Bangladesh 1
CY - Cipro 1
GE - Georgia 1
HR - Croazia 1
JM - Giamaica 1
LT - Lituania 1
MA - Marocco 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
TR - Turchia 1
UZ - Uzbekistan 1
Totale 55.415
Salva come PNG Salva come JPEG
Città #
Woodbridge 15.641
Wilmington 12.698
Houston 12.633
Ann Arbor 1.419
Fairfield 1.117
Jacksonville 662
Singapore 636
Ashburn 631
Chandler 621
Seattle 438
Dublin 398
Cambridge 376
Medford 312
Rome 255
New York 241
Dearborn 228
Beijing 224
Kraków 216
Santa Clara 155
Lawrence 149
Milan 128
Mülheim 113
Menlo Park 67
Zhengzhou 65
San Diego 59
Moscow 46
Mountain View 42
Boardman 39
Guangzhou 36
Redwood City 35
Falls Church 33
Civitavecchia 32
San Mateo 28
Palo Alto 26
University Park 26
Nanjing 23
Prague 21
Hefei 20
Verona 20
Naples 19
Norwalk 19
Shanghai 19
Turin 19
Ottawa 17
London 15
Florence 14
Palermo 14
Saint Petersburg 14
Bari 13
Brussels 13
Catania 13
Kunming 13
Phoenix 13
Toronto 13
Kansas City 12
Los Angeles 12
Munich 12
Nanchang 12
Napoli 12
Helsinki 11
Indiana 11
Torino 11
Brescia 10
Chicago 10
Nuremberg 10
Pune 10
Jinan 9
Pisa 9
Bologna 8
Brno 8
Fuzhou 7
Minervino Murge 7
Pioppi 7
Siena 7
Detroit 6
Engelhard 6
Hebei 6
Padova 6
Pavia 6
Pescara 6
Udine 6
Auburn Hills 5
Casalnuovo di Napoli 5
Chengdu 5
Kilburn 5
Nürnberg 5
Parma 5
Pordenone 5
San Francisco 5
Somma Lombardo 5
Ancona 4
Armenia 4
Athens 4
Cadeo 4
Cairo 4
Calusco d'Adda 4
Changsha 4
Cittaducale 4
Council Bluffs 4
Cremona 4
Totale 50.459
Salva come PNG Salva come JPEG
Nome #
Gli inibitori della poli (ADP-ribosio) polimerasi (PARP) per superare la chemioresistenza a metilanti e inibitori di topoisomerasi I 1.148
L’attività fisica come terapia complementare: l’esempio delle malattie oncologiche 656
Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells 471
Targeted therapy for brain tumours: role of PARP inhibitors 467
Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1 453
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells 452
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? 446
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity 444
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells 437
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide 436
Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity 428
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site 426
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma 425
Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes 423
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine 423
Challenging resistance mechanisms to therapies for metastatic melanoma 422
Immunopharmacology of antitumor agents. 421
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib 421
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. 420
Exploiting Microglial Functions for the Treatment of Glioblastoma 419
Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL) 417
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: Influence of 3'-azido-3'-deoxythymidine 417
Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of αvβ5 integrin. 416
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds 414
Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice. 414
Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy 414
Una medicina che cambia: l’approccio all’ipercolesterolemia. 414
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 413
Thymic selection of the T-cell repertoire 413
Chemical xenogenization: antigenic changes of cancer cells induced by triazene compounds 413
Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes 410
Pharmacological strategies to increase the antitumor activity of methylating agents 410
Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth 409
Effects of diheptyldiselenide (DDS) on human tumor cell lines and on peripheral blood mononuclear cells 405
Differentiation of Ia-reactive CD8+ murine T cells does not require Ia engagement. Implications for the role of CD4 and CD8 accessory molecules in T cell differentiation 404
null 404
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components 403
A novel water-soluble nitrobenzoxadiazole is highly effective against vemurafenib-resistant human melanoma cells 403
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines 401
Drug-mediated increase of susceptibility of human lung cancer to NK or LAK effector cells 398
Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin 397
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors 397
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase inhibitor 396
Chemotherapy in hairy cell leukemia. Preliminary results of a nonaggressive regimen 396
Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy 396
IL-2 reverses the inhibition of cytotoxic T-cell responses induced by 5-(3,3' dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vitro 396
Novel Glutathione S-Transferase Inhibitor Enhances Temozolomide Efficacy Against Malignant Melanoma 52nd Annual Meeting of the Italian Cancer Society. Lost in translation: bridging the gap between cancer research and effective therapies 395
Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers. 394
Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen 391
Inhibition of O-6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic coils to apoptosis induced by temozolomide 391
Primary cultures of microglial cells for testing toxicity of anticancer drugs. 390
Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 389
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 388
Role of PARP, NF-kB and telomerase in necrosis induced by selective methylation of N3-adenine. 386
Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma 386
DNA damaging agents can induce celll cycle arrest in different phases of mitosis 385
Role of DNA repair pathways in the control of common fragile sites expression. 385
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer 385
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. 383
Monoclonal antibodies to CTLA-4 with focus on ipilimumab 382
Induction of apoptosis in thymocytes by prostaglandin E2 in vivo 382
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. 381
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy 379
Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells 378
Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. 378
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma 378
Doping and Cancer 378
Modulation of GDF11 expression and synaptic plasticity by age and training 378
Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3 376
Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester 375
Inhibition of metastasis induced by triazene derivatives in mice bearing Lewis Lung Carcinoma (3LL): role of protein kinase C 375
VEGFR-1 derived peptide specifically inhibits PlGF and VEGF-B-induced migration of endothelial cells and in vivo angiogenesis. 374
New aspects of immune responses against mycobacteria: immunopharmacology studies 374
Influenza di farmaci antivirali o antimicobatterici sulla proliferazione di monociti umani e sulla espressione del CD1b. Secondo Progetto di ricerca Tubercolosi 371
Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro 371
The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells 371
In vitro antitumor activity of 3'-desamino-3'(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds 368
Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells 365
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent. 365
Acquired hemoglobin H disease in a case of refractory anemia with excess of blasts (RAEB) evolving into acute nonlymphoid leukemia 365
Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness. 365
Pharmacological inhibition of poly (ADP-ribose) polymerase (PARP) activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells and increases temozolomide sensitivity of PARP-1 silenced melanoma cells. 363
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan and temozolomide combination against colon carcinoma 363
MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. 363
PARP-1 inhibitor: a novel approach to enhance efficacy of chemotherapy. 362
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan against colon carcinomas 362
Systemic administration of the PARP inhibitor GPI 15427 increases the anti-tumor activity of temozolomide in melanoma, glioma and lymphoma preclinical models in vivo 359
Inhibition of poly(ADP-ribose) polymerase (PARP) increases the therapeutic efficacy of the G-quadruplex ligand RHPS4/irinotecan combination in colon cancer xenografts 359
Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant 358
Activity against melanoma of an anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody that does not hamper ligand binding 358
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 356
In vivo anti-angiogenic potential of a peptide that inhibits VEGFR-1 homodimerization and PlGF-induced migration of endothelial cells. 356
PARP inhibitors for cancer treatment: an update on current clinical trials. 356
PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets. 356
Temozolomide reduces the metastatic potential of Lewis-lung-carcinoma (3ll) in mice: role of alpha-6 integrin phosphorylation 355
Chemopotentiation by PARP inhibitors in cancer therapy 350
Oral administration of poly(ADP-ribose) polymerase inhibitor prevents intestinal damage induced by irinotecan and enhances the efficacy of irinotecan and temozolomide combination against colon carcinoma. 350
Apoptotic and clastogenic effects of methylating agents, alone or combined with poly(ADP-ribose) polymerase inhibitor, in peripheral blood lymphocytes 349
Inhibition of DNA repair enzyme potentiates apoptosis induced by temozolomide 349
Acute rejection of interferon-treated leukemia cells injected into lethally irradiated syngeneic mice 349
Totale 40.258
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.494
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.494
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202010.755 0 0 0 1.370 1.243 1.461 1.199 1.280 1.297 1.070 878 957
2020/20218.251 968 974 835 1.069 851 961 966 793 209 170 345 110
2021/20221.494 64 214 110 66 32 110 95 68 106 107 76 446
2022/20231.923 202 107 61 268 115 430 163 97 180 41 176 83
2023/20241.176 100 36 81 65 109 342 86 60 47 47 65 138
2024/20251.427 139 858 398 32 0 0 0 0 0 0 0 0
Totale 55.642